Get the Stockscreener App
29.00
1.16%
-0.3677
Immunocore Holdings Plc Adr stock is traded at $29.00, with a volume of 36,437.
It is down -1.16% in the last 24 hours and down -6.87% over the past month.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
See More
Previous Close:
$29.37
Open:
$29.78
24h Volume:
36,437
Relative Volume:
0.15
Market Cap:
$1.44B
Revenue:
$345.60M
Net Income/Loss:
$-79.01M
P/E Ratio:
-18.08
EPS:
-1.6045
Net Cash Flow:
$-18.62M
1W Performance:
-3.21%
1M Performance:
-6.87%
6M Performance:
-19.54%
1Y Performance:
-56.94%
1-Day Range:
$28.52
$30.01
1-Week Range:
$28.00
$31.44
52-Week Range:
$27.69
$68.43
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Name
Immunocore Holdings Plc Adr
Sector
Industry
Phone
01235 5430281
Address
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
29.00 | 1.44B | 345.60M | -79.01M | -18.62M | -1.6045 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.36 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.89 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.75 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.16 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.86 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-24 | Downgrade | Mizuho | Outperform → Neutral |
| Oct-24-24 | Initiated | UBS | Sell |
| Oct-07-24 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-23 | Initiated | Robert W. Baird | Outperform |
| Sep-13-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-13-23 | Initiated | Needham | Buy |
| Aug-16-23 | Initiated | CapitalOne | Overweight |
| Jul-17-23 | Initiated | Canaccord Genuity | Hold |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-30-23 | Initiated | Guggenheim | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Dec-16-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-30-22 | Initiated | Barclays | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| Sep-08-22 | Initiated | Ladenburg Thalmann | Buy |
| Aug-08-22 | Initiated | Cowen | Outperform |
| Aug-02-22 | Initiated | BTIG Research | Buy |
| Feb-08-22 | Initiated | H.C. Wainwright | Buy |
| Oct-20-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | Goldman | Neutral |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
| Mar-02-21 | Initiated | Jefferies | Buy |
View All
Immunocore Holdings Plc Adr Stock (IMCR) Latest News
Earnings call transcript: Immunocore Holdings Q4 2024 misses EPS - Investing.com
Immunocore Holdings earnings missed by $0.23, revenue fell short of estimates - Investing.com
Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store? - MSN
A stock that deserves closer examination: Empresa Distribuidora y Comercial Norte S.A. ADR (EDN) - US Post News
I-Mab ADR (IMAB) stock analysis: A simple moving average approach - US Post News
A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News
Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade - Yahoo Finance
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why - Zacks Investment Research
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 - Yahoo Finance
BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer - Yahoo Finance
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term - Yahoo Finance
Disappointing data leads to Immunocore stock downgrade by Morgan Stanley - Investing.com South Africa
Immunocore stock hits 52-week low at $29.23 amid market challenges - Investing.com
Immunocore's SWOT analysis: TCR pioneer's stock faces pivotal year - Investing.com
All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy - Yahoo Finance
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study - Yahoo Finance
New Strong Buy Stocks for December 12th - Yahoo Finance
Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals - Yahoo Finance
RZLT Stock Rises On FDA's Orphan Designation For Rare Disease Drug - Barchart
SNTI Stock Skyrockets On Initial Data From Phase I Cancer Study - Barchart
Altimmune Stock Up More Than 25% In A Month: Here's Why - Barchart
Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect? - MSN
Mirum Shares Surge More Than 90% in 6 Months: Here's Why - Yahoo Finance
Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know - MSN
New Strong Buy Stocks for November 26th - Yahoo Finance
Stack Capital Group announces normal course issuer bid - MSN
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - Barchart
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study - Nasdaq
What will it take for small caps to finally outperform large caps on earnings, performance? - MSN
Immunocore (IMCR) Upgraded to Buy: Here's Why - MSN
Immunocore's SWOT analysis: biotech stock faces pivotal moment amid PRAME data - Investing.com India
FATE Q3 Earnings Beat On Higher Revenues, Pipeline In Focus - Barchart
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark - Barchart
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised - Barchart
Mizuho downgrades Immunocore stock to Neutral, slashes PT to $38 from $72 - Investing.com
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline In Focus - Barchart
Immunocore repays Pharmakon loan, ends agreement - Investing.com India
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up - Barchart
Immunocore Holdings earnings beat by $0.50, revenue topped estimates - Investing.com India
Immunocore shares maintain buy rating on HIV treatment potential - Investing.com
Immunocore Holdings PLC (IMCR) Q2 2024 Earnings Call Highlights: Strong US Growth and Strategic ... - Yahoo Finance
Immunocore stock hits 52-week low at $29.72 amid market challenges - Investing.com
Immunocore's SWOT analysis: biotech stock poised for growth amid clinical trials - Investing.com UK
Financial Fitness Check: Examining Immunocore Holdings plc ADR (IMCR)’s Key Ratios - The Dwinnex
Immunocore stock hits 52-week low at $32.07 amid market challenges - Investing.com
Immunocore Holdings Plc Adr Stock (IMCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunocore Holdings Plc Adr Stock (IMCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| St Leger Tina Amber | CHIEF HR OFFICER |
Apr 01 '24 |
Sale |
64.06 |
4,375 |
280,262 |
0 |
3.23%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):